A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential【DOI: 10.1021/jm021093t】 Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model【 DOI: 10.1016/j.surg.2012.08.021】 Pasireotide (SOM230): development, mechanism of action and potential applications【 DOI: 10.1016/j.mce.2007.09.006】
